A shadow economy for unapproved weight-loss drugs is being driven by social media fitness personalities and vendors on messaging platforms, based on recent findings.
Experimental Treatment Gaining Traction Via Social Media
The experimental drug, which is still in research studies, is being advertised by social media influencers for its supposed weight-reducing properties. Followers are urged to message these profiles directly for supplier links, while also receiving discount codes.
Active Trade on Messaging Platforms
Separately, a robust trade exists on Telegram, where groups with numerous of participants share “before and after” photos, administration instructions and claims of next-day British shipping. Sellers promote the drug there before redirecting buyers to other platforms for transactions.
Learning About Retatrutide
Retatrutide is an investigational injection created by American pharmaceutical company Eli Lilly. The treatment affects three intestinal hormones – GLP-1, GIP and pancreatic hormone. Early trials suggest it could help individuals lose up to 25% of their body weight. Referred to as the “triple G”, the drug is being promoted online as the next Ozempic.
Medical Professionals Voice Concerns
Nevertheless, doctors and chemists have cautions that the distribution of what is still an unapproved drug in the United Kingdom is a cause for concern and could result in users administering substances of unknown origin.
Several professionals said the demand for retatrutide could be linked to the rising price of licensed slimming products such as Mounjaro.
Regulatory Position and Enforcement
Marketing the unapproved drug on social media or Telegram is illegal in the UK, as it is an unlicensed medication that cannot be marketed or supplied for personal consumption under the Human Medicines Regulations 2012.
Some influencers attempt to sidestep the rules by calling to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted drug, but promotion and supply can still breach medicines, advertising, and consumer regulations, risking penalties, legal action or imprisonment.
Service Response and Content Removal
According to the social media company, the platform has removed violative content and banned related hashtags and search suggestions. The organization stated it was committed to maintaining the platform safe and allocating resources in strengthening compliance measures.
Online Trading Activities
Research also found groups with up to 9,000 members selling retatrutide using the platform's integrated discovery tool, which operates like a public directory. Typing “retatrutide” instantly displays groups with numerous of members, filled with images of weight loss, glowing reviews and detailed instructions for mixing or injecting at home.
After minutes of joining one group, a seller posted contact information, where the majority of transactions take place. The seller provided an guidebook and guaranteed delivery within two days. When questioned whether the product was genuine, one seller said: “You can’t be sure.” Another shared a photo of a supposed testing documentation. Not one asked about body mass, medical conditions or previous experience.
Product Information and Pricing
Within these groups, posts show dark colored packages with postal service labels, claiming to contain fresh supplies. One communication read: “It took eight of us to load them this morning.”
Buyers can select between powder vials, mixed at residence with purified liquid, or pre-filled pens usually sold at £160 for 20mg. When questioned how much time a injector should be used, vendors give contradictory responses ranging from a several days to “depends on your body”.
Service Oversight and Security Actions
A spokesperson for the messaging service said it actively moderated harmful content on its platform including content that promoted the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.
Medical Expert Cautions
“Individuals are injecting substances they can’t verify. Even if the research behind this drug is valid, these digital products may not contain what they claim,” stated a pharmacy expert, the head of pharmaceutical services at a pharmacy service.
Dr Crystal Wyllie of Asda Online Doctor linked the increase in demand to current cost increases for approved slimming medications such as Mounjaro. “With costs increasing, individuals are turning to online platforms. But counterfeit treatments are highly dangerous. You can’t be certain what’s contained or whether the environment they were produced in was sterile,” she said.
Her team has previously seen individuals harmed by self-injection from unverified sources. “We understand the frustration, but purchasing from messaging apps or WhatsApp is taking chances with your health,” stated the doctor. “These materials could be contaminated or incorrectly dosed.”
Producer Statement
A spokesperson from the pharmaceutical company stated retatrutide was in phase 3 research studies and had not been evaluated or authorized by any regulatory agency globally. “Consequently at this point no one can market [it] for personal consumption,” they said, noting that any item “falsely representing itself as a company investigational substance not yet approved … may expose patients to potentially significant medical dangers”.
